Clinical Trials /

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

NCT04870034

Description:

This early phase I trial studies the direct effects on cancer cells of the drugs binimetinib and palbociclib, in patients with KRAS-positive lung, colorectal, or pancreatic cancer that can be removed by surgery (operable). Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and palbociclib may halt the growth of cancer cells and improve access of the immune system cells, a patient's own cells that fight infection and cancer, into the tumor.

Related Conditions:
  • Colorectal Carcinoma
  • Lung Adenocarcinoma
  • Pancreatic Carcinoma
Recruiting Status:

Not yet recruiting

Phase:

Early Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
  • Official Title: Perioperative Analysis of Binimetinib and Palbociclib in RAS-Driven Tumors

Clinical Trial IDs

  • ORG STUDY ID: I 797920
  • SECONDARY ID: NCI-2021-02908
  • SECONDARY ID: I 797920
  • NCT ID: NCT04870034

Conditions

  • Colorectal Carcinoma
  • Lung Adenocarcinoma
  • Malignant Solid Neoplasm
  • Pancreatic Carcinoma

Interventions

DrugSynonymsArms
BinimetinibARRY-162, ARRY-438162, MEK162, MektoviTreatment (palbociclib, binimetinib)
Palbociclib6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991Treatment (palbociclib, binimetinib)

Purpose

This early phase I trial studies the direct effects on cancer cells of the drugs binimetinib and palbociclib, in patients with KRAS-positive lung, colorectal, or pancreatic cancer that can be removed by surgery (operable). Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and palbociclib may halt the growth of cancer cells and improve access of the immune system cells, a patient's own cells that fight infection and cancer, into the tumor.

Detailed Description

      PRIMARY OBJECTIVE:

      I. To determine the on-target efficacy of binimetinib and palbociclib in patients with
      operable RAS-mutant lung adenocarcinoma, colorectal, or pancreatic cancer.

      SECONDARY OBJECTIVES:

      I. Correlative analysis of gene expression analysis. II. Define immune subsets within the pre
      and post-treatment tumor tissue.

      OUTLINE:

      Patients receive palbociclib orally (PO) once daily (QD) and binimetinib PO twice daily (BID)
      for 14 days in the absence of disease progression or unacceptable toxicity. Within 1 week
      after last dose of study medication, patients undergo surgery.

      After completion of study treatment, patients are followed up at 30 days.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (palbociclib, binimetinib)ExperimentalPatients receive palbociclib PO QD and binimetinib PO BID for 14 days in the absence of disease progression or unacceptable toxicity. Within 1 week after last dose of study medication, patients undergo surgery.
  • Binimetinib
  • Palbociclib

Eligibility Criteria

        Inclusion Criteria:

          -  Age >= 18 years of age

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Patients with verified and operable KRAS-positive mutant lung adenocarcinoma,
             colorectal, or pancreatic cancer

          -  Have available diagnostic, pre-treatment archival tumor tissue

          -  Medically fit for surgical resection

          -  Absolute neutrophil count (ANC) >= 1500/ uL

          -  Hemoglobin (Hgb) >= 9 g/dL

          -  Platelet count >= 100,000/uL

          -  Total bilirubin =< 1.5 x ULN (upper limit of normal)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN

          -  Creatinine clearance > 60 mL/min (Cockcroft-Gault Equation)

          -  Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
             criteria present

          -  Ability to swallow and retain oral medication

          -  Female participants of childbearing potential must agree to use methods of
             contraception that are highly effective or acceptable, and to not donate ova from
             screening until 30 days after the last dose of study drug. Should a woman become
             pregnant or suspect she is pregnant while she or her partner is participating in this
             study, she should inform her treating physician immediately

          -  Male participants must agree to use methods of contraception that are highly effective
             or acceptable, and to not donate sperm from screening until 90 days after the last
             dose of study drug

          -  Participant must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Prior therapy with a CDK4/6 (e.g. palbociclib, ribociclib) or MEK inhibitor (e.g.,
             binimetinib, trametinib, cobimetinib)

          -  Participants who have had any other systemic anticancer therapy within 2 weeks prior
             to entering the study

          -  Is currently participating in a study and receiving an investigational agent; has
             received an investigational agent within 14 days prior to start of study treatment

          -  Participants who have undergone major surgery =< 6 weeks prior to start of study
             treatment or who have not recovered from side effects of such procedure

          -  Patient has not recovered to =< grade 1 from toxic effects of prior therapy before
             starting study treatment. Note: Stable chronic conditions (=< grade 2) that are not
             expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related
             endocrinopathies) are exceptions and may enroll

          -  Uncontrolled or symptomatic brain metastases or leptomeningeal carcinomatosis that are
             not stable, require steroids, are potentially life-threatening or have required
             radiation within 28 days prior to starting study drug. Note: Patients with previously
             treated brain metastases may participate provided they are stable (e.g., without
             evidence of progression by radiographic imaging for at least 28 days before the first
             dose of study treatment and neurologic symptoms have returned to baseline), and have
             no evidence of new or enlarging brain metastases or central nervous system (CNS)
             edema, and does not require steroids at least 7 days before the first dose of study
             treatment

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Impaired cardiovascular function or clinically significant cardiac diseases including,
             but not limited to, any of the following:

               -  History of acute coronary syndromes (including myocardial infarction, unstable
                  angina, coronary artery bypass grafting, coronary angioplasty or stenting) < 6
                  months prior to screening

               -  Congestive heart failure requiring treatment (New York Heart Association grade >=
                  2)

               -  Left ventricular ejection fraction (LVEF) < 50% as determined by multigated
                  acquisition scan (MUGA) or echocardiography (ECHO)

               -  Uncontrolled hypertension defined as persistent systolic blood pressure >= 150
                  mmHg or diastolic blood pressure >= 100 mmHg despite current therapy

               -  History or presence of clinically significant cardiac arrhythmias (including
                  resting bradycardia, uncontrolled atrial fibrillation or uncontrolled paroxysmal
                  supraventricular tachycardia)

               -  Baseline corrected QT (QTc) interval >= 480 ms

          -  Impairment of gastrointestinal function or disease which may significantly alter the
             absorption of binimetinib or palbociclib (e.g., active ulcerative disease,
             uncontrolled vomiting or diarrhea, malabsorption syndrome, small bowel resection with
             decreased intestinal absorption), or recent (=< 3 months) history of a partial or
             complete bowel obstruction, or other conditions that will interfere significantly with
             the absorption of oral drugs

          -  Patients who have neuromuscular disorders that are associated with elevated creatine
             kinase (CPK) (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral
             sclerosis, spinal muscular atrophy)

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors to
             RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or
             hypercoagulability syndromes)

          -  Current use of a prohibited medication (including herbal medications, supplements, or
             foods) or use of a prohibited medication =< 1 week prior to the start of study
             treatment

          -  History of or cerebrovascular events =< 12 weeks prior to the first dose of study
             treatment

          -  History of pulmonary embolism (PE) with hemodynamic instability =< 12 weeks prior to
             first dose of study treatment. Note: Patients with PE that does not result in
             hemodynamic instability are allowed to enroll as long as they are on a stable dose of
             therapeutic anticoagulants for at least 4 weeks. Also, patients with deep vein
             thrombosis on stable dose of therapeutic anticoagulants for at least 4 weeks are
             allowed to participate in the study

          -  Concurrent or previous other malignancy that requires active anticancer therapy

          -  Known history of positive test for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS)

          -  Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

               -  Note: Patients with laboratory evidence of cleared HBV or HCV infection may be
                  enrolled

               -  Note: Patients with no prior history of HBV infection who have been vaccinated
                  against HBV and who have a positive antibody against hepatitis B surface antigen
                  as the only evidence of prior exposure may be enrolled

          -  Known history of acute or chronic pancreatitis =< 6 months prior to enrollment

          -  History of chronic inflammatory bowel disease or Crohn's disease requiring medical
             intervention (immunomodulatory or immunosuppressive medications or surgery) =< 12
             months prior to enrollment

          -  Known hypersensitivity to the components of study drugs or its analogs

          -  Pregnant or nursing female participants

          -  Unwilling or unable to follow protocol requirements

          -  Other severe, acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or study
             treatment administration or that may interfere with the interpretation of study
             results and, in the judgment of the Investigator, would make the patient an
             inappropriate candidate for the study

          -  The following special populations will not be included in the study:

               -  Cognitively impaired adults/adults with impaired decision-making capacity

               -  Individuals who are not yet adults (infants, children, teenagers)

               -  Pregnant women

               -  Prisoners
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Change in Ki67 labeling index of > 70%
Time Frame:Up to 30 days post treatment
Safety Issue:
Description:Pathologic response by change in Ki-67% from pre and surgical biopsies

Secondary Outcome Measures

Measure:Gene expression analysis
Time Frame:Up to 30 days post-treatment
Safety Issue:
Description:Correlative analysis of gene expression analysis will focus on suppression of MEK and CDK4/6 regulated genes and induction of gene expression programs related to antigen presentation and inflammation.
Measure:Immune subsets within the pre and posttreatment tumor tissue
Time Frame:Up to 30 days post-treatment
Safety Issue:
Description:Multispectral imaging will be employed to define immune subsets within the pre and posttreatment tumor tissue with an emphasis on approaches to exploit the response to drug with immunologically active agents.

Details

Phase:Early Phase 1
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Roswell Park Cancer Institute

Last Updated

June 1, 2021